Five Prime Therapeutics, Inc. (FPRX) financial statements (2020 and earlier)

Company profile

Business Address 111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18627029342251714976
Cash and cash equivalents4944608150158
Short-term investments13722623341436713468
Receivables45134400
Other undisclosed current assets813514722
Total current assets:19728931144052815178
Noncurrent Assets
Operating lease, right-of-use asset32
Property, plant and equipment2629316544
Restricted cash and investments  22   
Deferred costs    222
Other noncurrent assets2310010
Other undisclosed noncurrent assets22  13(2)(2)
Total noncurrent assets:61333382044
TOTAL ASSETS:25932234444854815682
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222537246173
Accounts payable4220210
Accrued liabilities1215281562 
Employee-related liabilities6778753
Taxes payable    46  
Deferred revenue2
Debt4      
Deferred rent credit 1
Deferred revenue and credits141518138
Contract with customer, liability1
Other undisclosed current liabilities      2
Total current liabilities:29275139792014
Noncurrent Liabilities
Long-term debt and lease obligation47      
Operating lease, liability47
Liabilities, other than long-term debt5292818325110
Deferred revenue and credits281832509
Deferred revenue5
Contract with customer, liability10
Deferred rent credit 18
Other liabilities   0001
Total noncurrent liabilities:52292818325110
Total liabilities:805679571127024
Stockholders' equity
Stockholders' equity attributable to parent1782652653924338558
Common stock0000000
Additional paid in capital579560421397373274210
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)00
Retained earnings (accumulated deficit)(401)(295)(156)(5)61(189)(152)
Total stockholders' equity:1782652653924338558
Other undisclosed liabilities and equity    3  
TOTAL LIABILITIES AND EQUITY:25932234444854815682

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net4031380  
Gross profit:16504031380  
Operating expenses(166)(196)(191)(130)(93)(57)(43)
Other undisclosed operating income     1914
Operating income (loss):(150)(146)(151)(99)287(38)(29)
Nonoperating income6632001
Investment income, nonoperating6632000
Other nonoperating income (expense)(0) (0) (0)(0)0
Income (loss) from continuing operations before income taxes:(145)(140)(149)(97)287(37)(29)
Income tax expense (benefit)  (2)31(38)  
Net income (loss) available to common stockholders, diluted:(145)(140)(150)(66)250(37)(29)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(145)(140)(150)(66)250(37)(29)
Other comprehensive income (loss)00(0)0(0)(0)(0)
Other undisclosed comprehensive income0      
Comprehensive income (loss):(144)(140)(151)(66)250(37)(29)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)      
Comprehensive income (loss), net of tax, attributable to parent:(144)(140)(151)(66)250(37)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: